0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Gut & Microbiome Sign in to save

Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome

Computational and Mathematical Methods in Medicine 2022 2 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 35 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Fenggang Lu, Yi Zhang, Pinghui Song, Yu Xu, Yu Xu, Zhongkun Wu, Qinyu Wang, Naiying Shen

Summary

Researchers investigated whether tanshinone IIA, a compound derived from Salvia miltiorrhiza, inhibits gastric cancer tumor growth through modulation of the intestinal microbiome and regulation of NF-kB signaling. The study found that tanshinone IIA altered the gut microbial composition and suppressed NF-kB pathway activity, suggesting a microbiome-mediated mechanism underlying its anti-tumor effects.

Body Systems

Tanshinone IIA may inhibit GC tumor growth via affecting the intestinal microbiome through regulating the NF-κB signaling.

Sign in to start a discussion.

More Papers Like This

Article Tier 2

Subchronic arsenic exposure induced intestinal flora dysbiosis and intestinal inflammation via activating the NF-κB signaling pathway

This mouse study found that subchronic arsenic exposure caused intestinal flora dysbiosis — altering bacterial community composition — and triggered intestinal inflammation through activation of the NF-κB signaling pathway, with consistent effects observed in both animal models and human colon epithelial cell cultures.

Clinical Trial Tier 1

Causal relationship between gut microbiota and gastrointestinal diseases: a mendelian randomization study

This Mendelian randomization study found genetic evidence supporting a causal relationship between specific gut microbiota compositions and gastrointestinal diseases. The findings suggest that microbiome-related interventions, including microbiome-dependent metabolites, could potentially be developed to treat or manage gastrointestinal conditions.

Clinical Trial Tier 1

Considering the Importance of Medicinal Plants and Natural Products and Their Mechanisms of Action for Treatment of Gastrointestinal Disorders

This bibliometric analysis of over a thousand articles reviewed medicinal plants and natural products for treating gastrointestinal disorders, highlighting their anti-inflammatory, antioxidant, and gut-protective mechanisms. While not focused on microplastics, the gut-protective properties of certain natural compounds are relevant to understanding how to mitigate gastrointestinal damage from environmental contaminants.

Article Tier 2

Erchen Decoction Alleviates High-Fat Diet + AOM/DSS-Induced CRC by Ameliorating Cholesterol-Bile Acid Metabolism Disorder through Regulating FXR and the Gut Microbiota

Researchers found that Erchen Decoction, a traditional Chinese medicine formula, alleviates colorectal cancer progression in a high-fat diet mouse model by correcting cholesterol-bile acid metabolism disorders through modulation of FXR signaling and gut microbiota composition.

Article Tier 2

Gastroprotective Effects of Periplaneta americana L. Extract Against Ethanol-Induced Gastric Ulcer in Mice by Suppressing Apoptosis-Related Pathways

Researchers examined the gastroprotective effects of Periplaneta americana extract against ethanol-induced gastric ulcers in mice, finding that the extract suppressed apoptosis-related pathways and protected gastric tissue from programmed cell death.

Share this paper